Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2018-05-09 AGM Information
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BT_2018-05-09_AGO-AGE 2018_Convocation_EN.pdf
AGM Information Classification · 99% confidence The document is explicitly titled 'INVITATION TO THE ORDINARY AND EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING' and details the agenda for this meeting, including resolutions regarding the approval of the annual report, remuneration report, annual accounts for the year ended 31 December 2017, director discharges, and appointments/confirmations of directors. The content is focused entirely on the proceedings and proposals for a shareholder meeting. This directly corresponds to the definition of AGM Information (AGM-R). Although it mentions the 'annual report' and 'auditor's report' (which might suggest 10-K or AR), the document itself is the invitation/agenda for the meeting where these items are discussed and approved, making AGM-R the most accurate classification.
2018-05-09 English
BT_2018-05-09_AGO-AGE 2018_Convocation_FR.pdf
AGM Information Classification · 99% confidence The document is explicitly titled "CONVOCATION À L'ASSEMBLÉE GÉNÉRALE ORDINAIRE ET À L'ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE" (Notice of Ordinary General Meeting and Extraordinary General Meeting). It details the agenda items for both meetings, which include the submission of the annual report, approval of remuneration reports, discharge of directors, and various capital structure changes (reduction of capital, renewal of authorized capital, issuance of warrants). This content is the formal notice and agenda sent to shareholders to solicit their vote and attendance at the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2018-05-09 French
PR_2018-05-04_BT_2017-Q1_EN_Final.pdf
Earnings Release Classification · 95% confidence The document is a 'Business Update' for the first quarter of 2018. It provides a summary of clinical trial progress, board appointments, and financial highlights (capital raised, cash balance, and cash burn outlook). While it contains financial data, it is structured as a press release/announcement of quarterly performance rather than a full, comprehensive interim financial report. In the context of financial filings, this type of summary document is classified as an Earnings Release (ER) as it provides the initial highlights of the period's performance. Q1 2018
2018-05-04 English
PR_2018-05-04_BT_2017-Q1_FR_Final.pdf
Earnings Release Classification · 99% confidence The document is explicitly titled "Bone Therapeutics publie son rapport d'activité du premier trimestre 2018" (Bone Therapeutics publishes its first quarter 2018 activity report) and details key operational and financial highlights for the period ending March 31, 2018. This content structure—a summary of quarterly performance, clinical trial updates, management changes, and key financial figures (cash balance, financing)—is characteristic of a comprehensive quarterly report, which aligns best with the 'Interim / Quarterly Report' definition (IR). Although it contains elements that might appear in an Earnings Release (ER), the depth of detail regarding clinical progress and financing structure suggests it is more than just the initial highlights release, making IR the most appropriate classification. Q1 2018
2018-05-04 French
PR_2018-05-04_BT_CB Denominator_EN_Final.pdf
Share Issue/Capital Change Classification · 98% confidence The document is dated May 4, 2018, and is titled "Information on the total number of voting rights and shares." It explicitly details an increase in the total number of shares and voting rights due to a recent issuance, referencing the Belgian Law of 2 May 2007 regarding major shareholdings. This content directly relates to changes in the company's share structure and voting rights denominator. This aligns perfectly with the definition of a Share Issue/Capital Change (SHA), as it reports the resulting share count after a capital event (conversion of convertible bonds). While it touches upon voting rights, the core subject is the change in the total number of shares outstanding, making SHA the most precise fit over DVA (which focuses on voting results) or CAP (which is broader financing).
2018-05-04 English
PR_2018-05-04_BT_CB Denominator_FR_Final.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions" (Information relating to the total number of voting rights and shares) and is dated May 4, 2018. It explicitly details the change in the total number of shares and voting rights following the conversion of convertible bonds, citing compliance with Belgian law regarding significant shareholdings. This content directly relates to changes in the company's capital structure and share count, which aligns best with the 'Share Issue/Capital Change' category (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend announcement (DIV).
2018-05-04 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.